A randomized, controlled trial of 685 adult COVID-19 outpatients in Brazil finds that neither the antimalaria drug hydroxychloroquine nor the antiviral drugs lopinavir-ritonavir significantly lowered rates of coronavirus–related hospitalizations when given soon after symptom onset.In the study, published today in JAMA Network Open, researchers from the Cardresearch-Cardiologica Assistencial e de Pesquisa enrolled COVID-19 outpatients with recent symptom onset in 10 cities in Brazil from Jun 2 to Oct 9, 2020.
The trial was stopped after the interim analysis owing to treatment futility. The study was part of the TOGETHER Trial to evaluate the effectiveness of repurposed therapies in high-risk, nonhospitalized, adult COVID-19 patients.No